Perjeta savings card: as little as $0 a treatment with commercial insurance

Perjeta is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Perjeta is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand namePerjeta

Authorized genericpertuzumab

Regular genericpertuzumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Perjeta?

The original

–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

The card takes up to $25,000 a year off your co-pay.

Or call 1-888-249-4918.

In the maker’s words

“With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $0 per treatment for PERJETA.”

From the maker’s offer on perjeta.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Perjeta itself, from the same company, sold without the brand name, and usually for less. For now Perjeta is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Perjeta is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

HER2-positive breast cancer

What the FDA label says

PERJETA is a HER2/neu receptor antagonist indicated for:

Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Use in combination with trastuzumab and chemotherapy as
- neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
- adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence

Source: the FDA label for Perjeta (Genentech, Inc.), April 30, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/perjeta/